RTI Surgical has received CE Mark approval for its Fortiva porcine dermis, a ready-to-use biologic implant that acts as a scaffold allowing for neovascularisation and permitting replacement of the implant with the patient’s tissue.

The implant is intended for use as a soft tissue path to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue membranes.

The non-crosslinked acellular porcine dermal matrix is indicated for use in repairing hernias and body wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome.

"Since its introduction in the US, we have seen the positive response from surgeons, and we are looking forward to offering this implant to surgeons here in Europe."

RTI Surgical Europe managing director Stefan Seuferling said: "Since its introduction in the US, we have seen the positive response from surgeons, and we are looking forward to offering this implant to surgeons here in Europe."

The ready-to-use porcine dermis requires no rehydration or rinsing and it also aids in efficiency in the OR, with a temperature indicator for quick indication of proper storage, rounded corners for ease of suturing and consistent thickness.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The implant is manufactured at RTI’s Neunkirchen, Germany facility and is available in a broad range of sizes, including 35×35 cm, which represents the largest biologics graft available in the market.

Fortiva is sterilised through RTI’s Tutoplast tissue sterilisation process and terminally sterilised via validated low-temperature, low-dose gamma irradiation to achieve a sterility assurance level (SAL) of 10-6.

Fortiva received 510(k) clearance from the US Food and Drug and Administration (FDA) in March 2013 and was launched in the US in July 2013.

The company also celebrated a milestone for Fortiva porcine dermis on May 23 2013, when a patient in Missouri received a 10x16cm graft for an incisional hernia repair using a component separation technique.